Quince Therapeutics, Inc. (IRLA) Financial Statements
Free cash flow over the same period: -$47.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
IRLAQuince Therapeutics, Inc.Follow IRLA — free
—
Price chart with a free account
- Market cap
- 33.6M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Research & development | 30.2 | 61.3 | 60.8 | 25.2 | 9.4 | 18.6 | 35.4 | 33.0 | |
| Operating income | -39.2 | -78.9 | -90.3 | -52.0 | -34.6 | -57.3 | -58.1 | -127.2 | |
| Pre-tax income | -37.0 | -76.8 | -89.9 | -51.9 | -31.6 | -56.7 | -80.8 | -94.6 | |
| Income tax | — | 0.0 | 0.0 | -0.3 | -0.2 | 0.1 | 3.2 | -2.2 | |
| Net income | -37.0 | -76.8 | -89.9 | -51.7 | -31.4 | -56.8 | -84.0 | -92.5 | |
| Diluted EPS ($) | -1.94 | -2.63 | -3.03 | -1.54 | -0.84 | -1.31 | -1.68 | -16.68 | |
| Diluted shares (mn) | — | — | — | 33.5 | 37.2 | 43.3 | 50.1 | — |
USD millions · SEC XBRL
Quince Therapeutics, Inc. — questions
- What is Quince Therapeutics, Inc.'s net income?
- -$92.5M over the twelve months to 2026-06-30.
- What is Quince Therapeutics, Inc.'s free cash flow?
- -$47.0M over the twelve months to 2026-06-30.
- What are Quince Therapeutics, Inc.'s diluted earnings per share?
- $-16.68 over the twelve months to 2026-06-30.
Every figure on this page comes from Quince Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.